NEOVACS: insider trades · France · AMF

About NEOVACS

Néovacs is a French biopharmaceutical company listed on Euronext Growth Paris under the ticker ALNEV. Founded in 1993 as a spin-off from Paris Sorbonne University, the company was originally built around a clear scientific ambition: to develop innovative active immunotherapies for inflammatory and autoimmune diseases, before broadening its scope toward other biotechnology asset-development opportunities. Historically, Néovacs became known for its proprietary Kinoid® platform, a patented technology designed to trigger a targeted immune response against selected cytokines or autoantigens. The company states that this technology is protected until 2040. Néovacs’ core business remains focused on research and development. The company continues to work on lupus, where it has completed a Phase IIb clinical study, and on allergies, with a particular emphasis on asthma. More recently, it has accelerated its shift toward mRNA-based approaches, highlighting preclinical results that it says outperform its legacy protein-based platform in a non-human primate model, especially for IL-4 and IL-13 targeting candidates. Néovacs has also announced a collaboration with CNRS and UTCBS to develop an mRNA therapeutic vaccine for asthma, as well as a second program targeting IgE in allergic diseases, supported by a grant from the French National Research Agency (ANR). From an industrial and market perspective, Néovacs is positioned as a small preclinical biotech company whose strategy relies on partnerships, co-financing, and selective asset monetization. The group now combines two activities: internal R&D and an investment business designed to support promising biotech and medtech projects. This dual model is intended to diversify value creation, but it also reflects the company’s dependence on financing capacity. Recent disclosures point to strict cost discipline, still-material funding needs, and restructuring measures, illustrating a high-risk profile but also strategic flexibility for a company of this size. Headquartered in Suresnes, France, Néovacs operates mainly through scientific collaborations with academic laboratories and partners. Its geographic footprint remains primarily French, but its development ambitions are international, particularly as it seeks future clinical development and possible value creation in Europe, the United States, and Asia depending on scientific and regulatory progress. Notable milestones include its stock market listing in 2010, its gradual repositioning toward mRNA, and recent discussions around strategic restructuring and potential transformational partnerships.